AEON Company Profile and Key Details

AEON has shown sold momentum, gaining 9.04% over the past week and 9.09% over the past quarter, though year-to-date performance is up 9.09%. Short-term trend indicators are bearishly aligned (SMA20 -2.15%, SMA50 -1.63%, SMA200 24.44%). The stock’s 14-day RSI is 47.84 (neutral), while the ATR of 0.11 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -46.57% below its high and over 190.67% above its low. Average 10-day trading volume of 45.41 thousand shares is below the 3-month average of 158.86 thousand, indicating normal recent market interest.

Analyst sentiment is bullish. Analyst rating data shows there are 0 Strong Buy ratings, 1 Buy ratings, 0 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $7.20 to $7.20. The high target offers 572.9% upside. The low target suggests 572.9% downside. The mean target is $7.20. This offers 572.9% upside. AEON Biopharma, Inc. earnings surprise history is frequent misses against expectations. The quarter that ended November 14, 2025, missed forecasts by -9.3%. The prior quarter beat by -99.34%. Over the last six quarters, Apple has recorded several small beats. These include -9.68% in May 14, 2024.

AEON Biopharma, Inc. has 25.30 million shares outstanding. The public float is 4.59 million shares, elevated short interest at 0.88% of float. This equals 221.97 thousand shares. The short ratio is 1.0 days. Institutional investors hold 18.83% of the float. Insiders own 14.87%. GLAZER CAPITAL, LLC holds 2.71 million shares, Strathspey Crown Holdings Group, LLC has 2.03 million shares and Forth Marc has 279.86 thousand shares.

AEON Biopharma, Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around -$5.54. This means the shares are trading below this model’s fair value.

Our AI price prediction model suggests that AEON Biopharma, Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected increase of 2.8%, with price expected at $1.10 by April 03, 2026, within a range of $1.01 to $1.18 3-Month Outlook: Projected fall of -96.26%, reaching $0.04 by June 18, 2026, with a range of $0.00 to $0.86. 1-Year Outlook: Projected loss of -100.0%, with price at $0.00 by March 19, 2027, within a range of $0.00 to $10.25.

AEON Biopharma, Inc. (AMEX:AEON) shares are flat 9.09% year-to-date currently trading near 52-week highs band. Short-term momentum has been positive over the last quarter, despite recent volatility. Valuation shows AEON Biopharma, Inc. trading at a premium to the broader market with a P/E of -4149.46. Analyst sentiment is bullish, with the majority of ratings in Buy territory and a mean price target of $9.87, suggesting 822.43% upside. Our AI forecast model points to short-term strength (2.8% over two weeks), a medium-term fall (-96.26% over three months), and a longer-term loss (-100.0% over one year), with expected trading ranges indicating moderate volatility.

AEON Biopharma, Inc. (AMEX:AEON) closed at $1.07 USD, losing -$0.06 (-5.31%) from the previous close of $1.13. The stock is currently mid-range between its 52-week high and low $0.38 and $1.45. With a market capitalization of about $12.66 million, AEON Biopharma, Inc. is classified as a micro-cap and shows lower-than-market volatility (beta ~0.71). Key stats such as the average daily volume over the past year has been around 158.11 thousand shares, volume is running light vs its 52-week average. Headquartered in Newport Beach, CA, AEON Biopharma, Inc. operates in the Healthcare sector and the Biotechnology industry. Led by CEO Robert Bancroft, the company employs approximately 5 people and listed since July 24, 2023. AEON Biopharma, Inc., a biopharmaceutical company, focuses on the development botulinum toxins for the treatment of debilitating medical conditions.

AEON Biopharma, Inc. trades at a P/E ratio of -4149.46, slightly below the S&P 500 average, with a price-to-sales ratio of 0.0 and a price-to-book ratio of -0.63 indicating negative book value, which may reflect financial stress. The P/FCF stands at -0.96, also above market averages.